Clearside Biomedical Inc expected to post a loss of 3 cents a share - Earnings Preview

Clearside Biomedical,

07/11/2022 17:25

* Clearside Biomedical Inc  CLSD.OQ   CLSD.O  is expected
to show
a rise in quarterly revenue when it reports  results on November
9. 
    * The Alpharetta Georgia-based  company is expected to
report  a
112.0% increase in revenue to $6.518 million from $3.07 million
a year ago, according to the mean estimate from 5 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Clearside
Biomedical Inc
is for a loss of 3 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Clearside
Biomedical Inc is $7​, above​ its last closing price of $1.49.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.13       -0.13      -0.13     Met     1.5
 Mar. 31 2022  -0.08       -0.08      -0.13     Missed  -58.5
 Dec. 31 2021  0.12        0.16       0.31      Beat    95.8​
 Sep. 30 2021  -0.10       -0.08      -0.08     Met     5.9
 ​​Jun.        -0.13       -0.13      -0.11     Beat    14.3
 30 2021                                                
 Mar. 31 2021  -0.11       -0.10      -0.13     Missed  -32.7​
 Dec. 31 2020  -0.11       -0.11      -0.14     Missed  -22.8
 Sep. 30 2020  -0.11       -0.12      -0.05     Beat    57.1
 This summary was machine generated November 7 at 17:25 GMT.  All
figures in US dollars  unless otherwise stated